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Abstract
We have previously shown that transgenic mice carrying a mutant human APP but deficient in
CD40L, display a decrease in astrocytosis and microgliosis associated with a lower amount of
deposited Aβ. Furthermore, an anti-CD40L treatment causes a diminution of Aβ pathology in the
brain and an improved performance in several cognitive tasks in the double transgenic PSAPP
mouse model. Although these data suggest a potential role for CD40L in Alzheimer's disease
pathology in transgenic mice they do not cast light on whether this effect is due to inhibition of
signaling via CD40 or whether it is due to the mitigation of some other unknown role of CD40L.
In the present report we have generated APP and PSAPP mouse models with a disrupted CD40
gene and compared the pathological features (such as amyloid burden, astrocytosis and microgliosis
that are typical of Alzheimer's disease-like pathology in these transgenic mouse strains) with
appropriate controls. We find that all these features are reduced in mouse models deficient for
CD40 compared with their littermates where CD40 is present. These data suggest that CD40
signaling is required to allow the full repertoire of AD-like pathology in these mice and that
inhibition of the CD40 signaling pathway is a potential therapeutic strategy in Alzheimer's disease.
Background
The extracellular deposition of the amyloid β-peptide
(Aβ) (which is  derived from the processing of the amy-
loid precursor protein [APP]) in  senile plaques and intra-
cellular accumulation of neurofibrillary tangles
(principally composed of phosphorylated tau protein) are
the main  pathological features of Alzheimer's disease
(AD) [1]. Besides these lesions, a continuous inflamma-
tory state exists in the brain of AD patients associated with
a secretion of pro-inflammatory cytokines around amy-
loid deposits. The inflammatory response is partly medi-
ated by microglial cells which have been found to be in an
activated state in the neighborhood of amyloid cores. It
also has been shown that microglia are activated by Aβ
exposure in vitro [2,3].
It is likely that many factors contribute to regulating the
microglial response to Aβ. Previous in vitro work shows
that Aβ-induced microglial activation is greatly enhanced
by stimulation of the CD40 pathway, and that secretion of
tumor necrosis factor alpha and neuronal death occur
when Aβ-treated microglia are challenged with CD40 lig-
and, CD40L [3]. Other evidence supports an important
role for CD40 and CD40L in AD. For instance, the pattern
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of expression of these proteins is altered in the brain in AD
patients as well as in several animal models of AD [4,5].
In addition, the expression of both APP-processing related
genes and genes related to tau-phosphorylation is dis-
turbed in cultured human microglia after treatment with
CD40L [6]. Finally, we have shown that mice that express
non-functional CD40L and human APPsw (APP Swedish,
a mutant form of APP that increases the production of
Aβ), reduce AD-related pathology such as microgliosis,
astrocytosis and Aβ load [7]. Furthermore, an anti-CD40L
antibody improves the cognitive function and the AD-
related pathology in a double transgenic mouse model
(PSAPP) that express human presenilin and human APPsw
[7,8].
Although a role of CD40L in AD-like pathology in trans-
genic mice is confirmed by these previous experiments
they do not indicate whether CD40 signaling is a neces-
sary requirement for full AD pathology in these models.
We thus decided to test whether genetic disruption of
CD40 would have a similar effect on the reduction of AD-
like pathology as did the removal of functional CD40L.
We have generated APPsw and PSAPP mouse models defi-
cient for functional CD40 expression and compared the
pathological features such as amyloid burden, CD45 and
GFAP expression that are typical of AD-like pathology in
these transgenic mouse strains with appropriate controls.
Methods
Animals
CD40 disrupted mice were purchased from the Jackson
Laboratory. This genetic variation occurs on the C57BL/6
background, constructed as described [9]. Tg APPsw mice
of the 2576 line had a C57B6/SJL background as
described [10]. We crossed CD40 disrupted mice with Tg
APPsw or Tg PSAPP (double transgenic mice with APPsw
and mutated PS1M146L obtained as described in [11]).
The crossed mice obtained will be further referred as: Tg
APPsw/CD40 deficient (def.) and Tg PSAPP/CD40 def. The
offspring were characterized by polymerase chain reac-
tion-based genotyping for mutant APP and PS1 constructs
(to determine Tg APPsw and PS1M146L status respec-
tively) and for the neomycin selection vector (to type for
CD40 deficiency). These mice were then killed at 22 to 24
months of age for pathologic analysis. Littermates were
used as controls throughout. Animals were given food and
water ad libitum. They were housed and maintained in the
Roskamp Institute Animal Facility, and all experiments
were in compliance with protocols approved by the
Roskamp Institute Institutional Animal Care and Use
Committee.
Brain preparation
Mice were anesthetized with isoflurane, then the brains
(Control, Tg APPsw, CD40 def., TgAPPsw/CD40 def.,
PSAPP/CD40 def. and PSAPP) were isolated under sterile
conditions on ice. One hemisphere of each brain was
immersed in 4% paraformaldehyde at 4°C overnight, and
routinely processed in paraffin. Briefly, the hemispheres
were embedded into paraffin using Tissue-Tek (Sakura,
USA) and sagitally cut into 6-um-thick sections with a
microtome (2030 Biocut, Reichert/Leica, Germany). Sec-
tions were mounted on slides, air-dried and stored until
needed. The second hemisphere was placed in ice-cold
lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerolphosphate, 1 mM
Na3VO4, 1 µg/mL leupeptin, 1 mM PMSF), then sonicated
on ice for approximately 3 min, let stand for 15 min at
4°C, and centrifuged at 15,000 rpm for 15 min.
Total Aβ extraction and quantification
Total Aβ species were detected by acid extraction of brain
homogenates. Insoluble Aβ species were extracted by 70%
formic acid as previously published [12]. Aβ content in
brain was determined using human Aβ 1–40 and Aβ 1–42
ELISA kits (BioSource, Camarillo, CA) in accordance with
the manufacturer's instruction. Data are expressed as pg/
mg protein, mean ± s.e.m.
Antibodies
Monoclonal antibody AT8 (Pierce Biotechnology, IL)
which recognizes human phosphorylated tau at Ser202
and Thr205 was diluted 1:400. CD45 was immunode-
tected using a 1:50-dilution of a rat monoclonal antibody
(clone IBL-3/16) from Serotec, NC. Rabbit anti-cow glial
fibrillary acidic protein (GFAP) was used at 1:1000 (Dako-
cytomation, CA). Monoclonal antibody 4G8 was used to
stain Aβ deposits at a 1:750-dilution and purchased from
Signet Laboratories, MA. Rabbit anti-Aβ 1–40 and rabbit
anti-Aβ 1–42 were used at 1:100 and provided by Chemi-
con, CA. F4/80 antigen was detected using a rat antibody
(clone CI:A3-1 from Serotec) diluted 1:50.
Immunohistochemistry and Congo red staining
Prior to staining, sections were deparaffinized in xylene (2
× 5 min) and hydrated in graded ethanol (2 × 5 min in
100%, 5 min in 85%, 5 min 70%) to water.
Endogeneous peroxidase activity was quenched with a 20-
min-H2O2  treatment (0.3% in water) and after being
rinsed, sections were incubated with blocking buffer (Pro-
tein Block Serum-free, DakoCytomation) for 20 min. The
diluted antibodies were applied onto the sections over-
night at 4°C. They were detected using the Vectastain ABC
(avidin-biotin-peroxidase complex) Elite kit (Vector Lab-
oratories, CA) and the labeling was revealed by incubating
sections in 0.05 M Tris-HCl buffer (pH 7.6), containing
3,3'-diaminobenzidine (Sigma, MO) and H2O2.Journal of Neuroinflammation 2006, 3:3 http://www.jneuroinflammation.com/content/3/1/3
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Congo red staining was performed using the kit from
Sigma according to the manufacturers' indications.
For each brain, 4 to 5 stained sections were used to per-
form the quantification. The stained area within particular
regions (hippocampus, cortex or  subfields of cortex) was
quantified using the Image-Pro Plus software (Media
Cybernetics, MD). An average value was calculated for
each area from individual mice. These averages were used
to estimate the overall staining for each genotype. The
relationships between staining in each brain area and gen-
otype were examined by one-way analysis of variance and
post hoc test.
Results
Both Tg APPsw/CD40 def. and Tg PSAPP/CD40 def. show
decrease in 4G8-positive plaques compared to their Tg
APPsw and Tg PSAPP littermates. There is a reduction in
brain area specific amyloid load in the Tg APPsw/CD40
def. mice by 38% (occipital cortex) to 66% (parietal cor-
tex) (Table 1). Similarly, the PSAPP/CD40 def. mice show
65% (hippocampus) to 73% (occipital cortex) reduction
compared to their Tg APPsw and Tg PSAPP littermates. In a
post hoc comparison of the means, only the differences in
the parietal cortex and hippocampus were significant in
the Tg APPsw vs Tg APPsw/CD40 def. mice (Fig. 1a and Fig.
2). By contrast, all brain areas showed significant post hoc
differences for the PSAPP vs PSAPP/CD40 def. mice (Fig.
1b and Fig. 3).
As shown in Fig. 4a and 4b, ELISA analysis of formic-
extracted Aβ produced results consistent with the above
findings (mean Aβ, pg/mg of protein brain ± s.e.m., Tg
APPsw mice vs Tg APPsw/CD40 def.; 30% reduction in
Aβ1–40 and 80% in Aβ1–42 [1,249,460 ± 110,868.31 vs
728,181.33 ± 142,274.44 and 212,631.87 ± 21,453.03 vs
42,266.92 ± 5,782.35 respectively]. Tg PSAPP mice vs Tg
PSAPP/CD40 def.; 45% reduction in Aβ1–40 and 70%
Percentages of 4G8-positive β-amyloid plaques (mean ±  s.e.m) by area in (a) Tg APPsw/CD40 def. mice versus Tg  APPsw mice and in (b) Tg PSAPP/CD40 def. mice versus Tg  PSAPP mice at 22 to 24 months of age calculated by quantita- tive image analysis Figure 1
Percentages of 4G8-positive β-amyloid plaques (mean ± 
s.e.m) by area in (a) Tg APPsw/CD40 def. mice versus Tg 
APPsw mice and in (b) Tg PSAPP/CD40 def. mice versus Tg 
PSAPP mice at 22 to 24 months of age calculated by quantita-
tive image analysis. Post hoc comparison between groups are 
indicated by the marked bars (* p < 0.05 ; ** p < 0.01 ; *** p 
< 0.001).
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Table 1: Value of 4G8-positive β-amyloid plaques and percentage 
of reduction when CD40 is disrupted in Tg APPsw and Tg PSAPP 
mice.
Genotype Studied area 4G8-positive plaque 
(% of area)
Variation (%) 
when compared 
to control
Tg APP>sw
Frontal cortex 1.75 ± 0.29 n/a*
Occipital cortex 2.20 ± 0.46 n/a
Parietal cortex 3.22 ± 0.48 n/a
Hippocampus 2.67 ± 0.45 n/a
Tg APPsw/CD40 def.
Frontal cortex 1.06 ± 0.24 40% reduction
Occipital cortex 1.37 ± 0.33 38% reduction
Parietal cortex 1.11 ± 0.32 66% reduction
Hippocampus 0.97 ± 0.30 63% reduction
Tg PSAPP
Frontal cortex 7.06 ± 0.96 n/a
Occipital cortex 6.77 ± 1.01 n/a
Parietal cortex 6.39 ± 1.03 n/a
Hippocampus 6.99 ± 0.93 n/a
Tg PSAPP/CD40 def.
Frontal cortex 2.34 ± 0.41 67% reduction
Occipital cortex 1.80 ± 0.19 73% reduction
Parietal cortex 2.19 ± 0.39 66% reduction
Hippocampus 2.47 ± 0.43 65% reduction
*non applicableJournal of Neuroinflammation 2006, 3:3 http://www.jneuroinflammation.com/content/3/1/3
Page 4 of 10
(page number not for citation purposes)
reduction in Aβ1–42 [2,868,709.33 ± 198,843.63 vs
1,298,021.33 ± 133,263.81 and 337,169.33 ± 28,240.97
vs 102,307.33 ± 5,363 respectively]).
Staining of Tg APPsw and Tg APPsw/CD40 def. brain with
specific antibodies directed against Aβ1–40 and Aβ1–42 and
analysis of their parenchymal or vascular localization
have been performed. As expected, the overall immunos-
taining for Aβ1–40 and Aβ1–42 was reduced by 43% and
38% respectively, in Tg APPsw/CD40 def. mice when
compared to Tg APPsw. However, an analysis of the
parenchymal and vascular deposits of each Aβ species
showed that only the parenchymal-deposited Aβ1–40 and
Aβ1–42 was reduced when CD40 is disrupted, whereas the
vascular-associated Aβ is essentially unchanged (Fig. 5a
and 5b). Consequently, the vascular Aβ1–40 represented
20% of the total Aβ1–40 in Tg APPsw, whereas it represented
40% in Tg APPsw/CD40 def. The values are 36% and 64%
respectively for vascular Aβ1–42.
The disruption of the CD40 gene in Tg APPsw and in Tg
PSAPP mice leads to a decrease of reactive astrocytes quan-
tified by GFAP staining and image analysis (34% reduc-
tion in the hippocampus and 53% reduction in the cortex
of Tg APPsw/CD40 def.; 32% reduction in the hippocam-
pus and 33% reduction in the cortex of Tg PSAPP/CD40
def.) (Fig. 6).
There was a concomitant reduction in CD45-stained
microglia which was reduced by 37% in the hippocampus
and 46% in the cortex when CD40 is disrupted in Tg
APPsw (Fig. 7a, c and 7e). The reduction reached 55% (hip-
pocampus) and 65% (cortex) when PSAPP/CD40 def. and
PSAPP mice are compared (Fig. 7b, d and 7f).
Representative photographs of frontal, occipital and parietal cortical areas and hippocampus in Tg APPsw and Tg APPsw/CD40  def. stained with 4G8 antibody Figure 2
Representative photographs of frontal, occipital and parietal cortical areas and hippocampus in Tg APPsw and Tg APPsw/CD40 
def. stained with 4G8 antibody (each bar represents 0.2 mm; FC : frontal cortex; OC : occipital cortex; PC : parietal cortex; 
Hip: hippocampus).Journal of Neuroinflammation 2006, 3:3 http://www.jneuroinflammation.com/content/3/1/3
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Since CD40 deficiency could impair the development or
differentiation of microglia in mice, we have stained brain
sections of 8 to 10 weeks old mice for F4/80 antigen. As
shown in Fig. 8, no difference was observed between
CD40 def. mice and wild type mice. Quantification of the
stained area confirmed the observation: 15.68 ± 1.23 %
and 12.51 ± 1.76 % of the cortex were stained for F4/80 in
CD40 def. mice and wild type mice respectively.
It has been shown that congophilic plaques are associated
with phosphorylated tau-immunoreactive aberrant struc-
tures in Tg APPsw [13]. Therefore, we explored the pres-
ence of these structures using an anti-phosphorylated-tau
antibody AT8 (tau phosphorylated at Ser202 and Thr205)
in the transgenic mice. These structures were exclusively
associated with congophilic plaques and were not found
in the control mice. The mean ratio of areas of phosphor-
ylated tau to Congo red in Tg APPsw is unchanged with age
(from 11 to 20.5 months old) and is approximately 10%
as previously reported [13]. We have found a similar ratio
in these mice at 22 to 24 months old and the genetic dele-
tion of CD40 did not disrupt this ratio in either Tg APPsw
or Tg PSAPP mice. However, as the total amyloid burden
was reduced in the CD40 def. animals, overall there was a
concomitant reduction in AT8-positive staining (data not
shown).
Discussion
It has previously been shown that reduction of functional
CD40L mitigates AD like-pathology in transgenic mouse
models of AD [3,7]. The mechanism of this effect is not
known but an obvious possibility is that CD40L promotes
AD-like pathology by activating CD40. Other possibilities
include a direct role of CD40L in Aβ fibrillogenesis or oli-
Representative photographs of frontal, occipital and parietal cortical areas and hippocampus in Tg PSAPP and Tg PSAPP/CD40  def. stained with 4G8 antibody Figure 3
Representative photographs of frontal, occipital and parietal cortical areas and hippocampus in Tg PSAPP and Tg PSAPP/CD40 
def. stained with 4G8 antibody (each bar represents 0.2 mm; FC : frontal cortex; OC : occipital cortex; PC : parietal cortex; 
Hip: hippocampus).Journal of Neuroinflammation 2006, 3:3 http://www.jneuroinflammation.com/content/3/1/3
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gomer formation. In order to test whether CD40 transduc-
tion is needed to promote AD-like pathology in these
transgenic mouse models, we examined transgenic mice
with and without functional CD40. All the pathological
evidence suggests that CD40 itself is required to promote
amyloid, tau and glial pathologies.
The mitigation of all these pathologies is greatest in the
transgenic animals with most amyloid over-expression.
This observation may be due to the fact that more accurate
quantification is possible when pathologies are denser or
it may truly reflect a rate limiting step imposed by CD40.
We have recently shown in a genomic study that CD40
ligation of microglia specifically up-regulates APP metab-
olism and tau phosphorylation related genes [6].
Although microglia do not produce Aβ, it is possible that
in neurons (where CD40 is expressed [14]) CD40 ligation
may enhance Aβ production. This may be also true in
astrocytes [15,16].
Additionally, the activation of microglia by CD40L may
enhance the inflammatory response in these mouse mod-
els and promote Aβ production from neurons. For
instance CD40L-stimulated microglia release IL1β and α
which increase APP expression and IL1β increases APP
metabolism to Aβ [17,18].
Thus, in the presence of a fully functional CD40 transduc-
tion and Aβ, microglia may be highly activated (compared
to their response when CD40 transduction can not take
place [3]) and in turn, may induce further Aβ production
Total, vascular or parenchymal-deposited (a) Aβ1–40 and (b)  Aβ1–42 expressed as a percentage (mean ± s.e.m) of the area  studied in Tg APPsw/CD40 def. mice versus Tg APPsw mice at  22 to 24 months of age calculated by quantitative image anal- ysis Figure 5
Total, vascular or parenchymal-deposited (a) Aβ1–40 and (b) 
Aβ1–42 expressed as a percentage (mean ± s.e.m) of the area 
studied in Tg APPsw/CD40 def. mice versus Tg APPsw mice at 
22 to 24 months of age calculated by quantitative image anal-
ysis. Post hoc comparison between groups are indicated by 
the marked bars (* p < 0.05).
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Formic-extracted (a) Aβ1–40 and (b) Aβ1–42 (mean ± s.e.m)  measured by ELISA in Tg APPsw, Tg PSAPP, Tg APPsw/CD40  def. and Tg PSAPP/CD40 def Figure 4
Formic-extracted (a) Aβ1–40 and (b) Aβ1–42 (mean ± s.e.m) 
measured by ELISA in Tg APPsw, Tg PSAPP, Tg APPsw/CD40 
def. and Tg PSAPP/CD40 def. Post hoc analysis between 
groups are indicated by the marked bars (* p < 0.05; *** p < 
0.001).
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via neuro-inflammation. It is interesting to note that the
presence of CD40 promotes parenchymal deposition of
Aβ but does not impact vascular deposits. It maybe that
CD40 only impacts production of Aβ from parenchymal
but not vascular cells. Alternatively, it is possible that
CD40 impairs the transfer of Aβ across the blood-brain
barrier and that its deficiency facilitates the transport of
parenchymal Aβ to the periphery. Disproportionate accu-
mulation of Aβ in or around the vasculature might occur
under these circumstances.
The downstream signaling events in the CD40 pathway
which lead to Aβ production and tau phosphorylation
need further exploration. In particular, it will be impor-
tant to separate NF-κ b-induced pro-inflammatory
responses known to occur in microglia from other NF-κ b
signaling directly related to APP processing. As Aβ itself
can activate NF-κ b (which is enhanced in AD brain) both
activated CD40 and Aβ may synergistically enhance NF-κ
b signaling resulting in feed-forward Aβ production with
the consequent cascade of other AD pathologies.
List of abbreviations
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Percentage of microgliosis (mean ± s.e.m) by area in (a) Tg APPsw/CD40 def. mice versus Tg APPsw mice and in (b) Tg PSAPP/ CD40 def. mice versus Tg PSAPP mice at 22 to 24 months of age calculated by quantitative image analysis Figure 7
Percentage of microgliosis (mean ± s.e.m) by area in (a) Tg APPsw/CD40 def. mice versus Tg APPsw mice and in (b) Tg PSAPP/
CD40 def. mice versus Tg PSAPP mice at 22 to 24 months of age calculated by quantitative image analysis. Post hoc compari-
son between groups are indicated by the marked bars (* p < 0.05; ** p < 0.01). Representative photographs of brain area in (c) 
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